Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
46
TELO Quote, Financials, Valuation and Earnings
Last price:
$1.46
Seasonality move
:
27.19%
Day range:
$1.39 - $1.46
52-week range:
$1.12 - $5.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.19x
Volume:
187.7K
Avg. volume:
448.3K
1-year change:
-69.65%
Market cap:
$50.2M
Revenue:
--
EPS (TTM):
-$0.37
Earnings Data
Next earnings date for TELO
--
Most recent earnings per share
-$0.03
Beat by $0.04
(Nov 12/2025)
Consensus Estimate
-$0.07
(Nov 12/2025)
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
TELO Quarterly Earnings History
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 12/31/2025 | Q4 | -- | -- | -- | -$0.07 | -- |
| 11/12/2025 | Q3 | -- | -- | -$0.03 | -$0.07 | $0.04 |
| 08/14/2025 | Q2 | -- | -- | -$0.17 | -$0.08 | -$0.09 |
| 05/14/2025 | Q1 | -- | -- | -$0.07 | -$0.10 | $0.03 |
| 02/28/2025 | Q4 | -- | -- | -$0.10 | -$0.05 | -$0.05 |
| 11/12/2024 | Q3 | -- | -- | -$0.20 | -- | -- |
| 08/13/2024 | Q2 | -- | -- | -$0.05 | -- | -- |
| 03/31/2024 | Q1 | -- | -- | -$0.23 | -- | -- |
| 12/31/2023 | Q4 | -- | -- | -$0.32 | -- | -- |
| 09/30/2023 | Q3 | -- | -- | -$0.06 | -- | -- |
| 06/30/2023 | Q2 | -- | -- | -$0.05 | -- | -- |
| 03/31/2023 | Q1 | -- | -- | -$0.02 | -- | -- |
| 12/31/2022 | Q4 | -- | -- | -$0.02 | -- | -- |
| 09/30/2022 | Q3 | -- | -- | -$0.01 | -- | -- |
| 06/30/2022 | Q2 | -- | -- | -$0.00 | -- | -- |
| 03/31/2022 | Q1 | -- | -- | -$0.00 | -- | -- |
Telomir Pharmaceuticals, Inc. Earnings Questions
-
How Much did Telomir Pharmaceuticals, Inc. Generate in Revenue Last Quarter?
Telomir Pharmaceuticals, Inc. reported -- worth of top line sales in its most recent quarter.
-
Did Telomir Pharmaceuticals, Inc. Beat Earnings Last Quarter?
Telomir Pharmaceuticals, Inc. announced earnings per share of -$0.03 which represents a beat of analyst forecast a -$0.07 per share.
-
Is Telomir Pharmaceuticals, Inc. Profitable?
Telomir Pharmaceuticals, Inc. reported -- that represents -- per share over the last quarter.
-
What is the Analyst Consensus for Telomir Pharmaceuticals, Inc. EPS Next Year?
Telomir Pharmaceuticals, Inc.'s earnings are forecast to decrease from -$0.56 per share to -$0.54 per share next year representing a decrease of -32.11%.
-
When is Telomir Pharmaceuticals, Inc.'s Earnings Date?
Currently, Telomir Pharmaceuticals, Inc. has not yet stated when its earnings date is, however, based on past estimates it's likely to take place on March 29, 2026.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
